UB Paderborn / Katalog / Suche / in CDI

1 – 21 von 21

Sortiert nach

Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases

Advances in rheumatology (London, England), 2023-06, Vol.63 (1), p.25-25, Article 25

2023

Volltextzugriff (PDF)

Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety

Pain (Amsterdam), 2020-09, Vol.161 (9), p.2068-2078

2020

Volltextzugriff (PDF)

Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry

Arthritis research & therapy, 2024-02, Vol.26 (1), p.57-57, Article 57

2024

Volltextzugriff (PDF)

Retention of golimumab treatment following discontinuation of non‐TNF inhibitors in patients with inflammatory rheumatic diseases: An analysis of the Spanish BIOBADASER registry

Musculoskeletal care, 2022-06, Vol.20 (2), p.403-407

2022

Volltextzugriff (PDF)

Infection by Mycobacterium chelonae at the site of administration of sarilumab for rheumatoid arthritis

Rheumatology (Oxford, England), 2020-01, Vol.59 (1), p.265-265

2020

Volltextzugriff (PDF)

Adherence to Treatment in Patients with Rheumatoid Arthritis from Spain

Patient preference and adherence, 2021-01, Vol.15, p.111-117

2021

Volltextzugriff (PDF)

The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs

Pharmacological research, 2019-10, Vol.148, p.104410-104410, Article 104410

2019

Volltextzugriff (PDF)

European bio-naïve spondyloarthritis patients initiating TNFi: Time trends in baseline characteristics, treatment retention and response

Rheumatology (Oxford, England), 2021-12

2021

Volltextzugriff (PDF)

Abatacept for the treatment of rheumatoid arthritis

Expert review of clinical immunology, 2019-04, Vol.15 (4), p.319-326

2019

Volltextzugriff (PDF)

After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries

Annals of the rheumatic diseases, 2023-02, Vol.82 (2), p.175

2023

Volltextzugriff (PDF)

Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries

Arthritis care & research (2010), 2022-07, Vol.74 (7), p.1205-1218

2022

Volltextzugriff (PDF)

Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies

Joint, bone, spine : revue du rhumatisme, 2024-03, Vol.91 (2), p.105671-105671, Article 105671

2024

Volltextzugriff (PDF)

Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry

Clinical rheumatology, 2021-10, Vol.40 (10), p.3979-3988

2021

Volltextzugriff (PDF)

European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response

Rheumatology (Oxford, England), 2022-08, Vol.61 (9), p.3799-3807

2022

Volltextzugriff (PDF)

Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration

Rheumatic & musculoskeletal diseases open, 2020-09, Vol.6 (3), p.e001280

2020

Volltextzugriff (PDF)

Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis – relationship with the reason for withdrawal from the previous treatment

Joint, bone, spine : revue du rhumatisme, 2024-07, Vol.91 (4), p.105729, Article 105729

2024

Volltextzugriff (PDF)

Risk/benefit management in the infectious phase in systemic autoimmune rheumatic diseases

Handbook of Systemic Autoimmune Diseases, 2020, Vol.16, p.179-203

2020

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(15)

Publikationsform

Artikel
(20)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(19)
Science & Technology
(19)
Rheumatology
(16)
Humans
(12)
Rheumatoid Arthritis
(11)
Antirheumatic Agents - Therapeutic Use
(9)
Arthritis, Rheumatoid - Drug Therapy
(9)
Patients
(7)
Psoriatic Arthritis
(7)
Medicin Och Hälsovetenskap
(6)
Retention
(6)
Treatment Outcome
(6)
Axial Spondyloarthritis
(5)
Epidemiology
(5)
Tnf Inhibitors
(5)
Antirheumatic Agents
(4)
Golimumab
(4)
Monoclonal Antibodies
(4)
Registries
(4)
Rheumatic Diseases
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases

Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety

Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry

Retention of golimumab treatment following discontinuation of non‐TNF inhibitors in patients with inflammatory rheumatic diseases: An analysis of the Spanish BIOBADASER registry

Infection by Mycobacterium chelonae at the site of administration of sarilumab for rheumatoid arthritis

Long‐term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis

The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis

Adherence to Treatment in Patients with Rheumatoid Arthritis from Spain

The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs

European bio-naïve spondyloarthritis patients initiating TNFi: Time trends in baseline characteristics, treatment retention and response

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration

Abatacept for the treatment of rheumatoid arthritis

After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries

Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)

Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries

Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies

Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry

European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response

Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration

Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis – relationship with the reason for withdrawal from the previous treatment

Risk/benefit management in the infectious phase in systemic autoimmune rheumatic diseases

Aktive Filter

Suchergebnisse filtern